Company Overview and News

9
Solid EM Micro Despite Macro Angst

8h seekingalpha
It has certainly been a challenging quarter, leading to conflicting and bifurcated views on the emerging markets asset class and contrasting macro angst with solid bottom-up metrics. Despite a fairly robust global economic and profit growth backdrop and reasonable valuations, investor sentiment is negative.
HTHT SSNLF CMLLF HDB 1317 500180 BC94 SMSN HDFCBANK SUPV SMSD

1
HDFC Bank Q1 Preview: PAT seen rising 23% on stable asset quality, interest income

12h moneycontrol
HDFC Bank, the country's largest private sector lender, is expected to post a 23 percent rise in its June quarter net profit to Rs 4,785.3 crore on stable asset quality and interest income, according to a Reuters poll of analysts.
HDB 500180 HDFCBANK

1
PN Gadgil gets SEBI nod for IPO

2018-07-19 thehindubusinessline
PN Gadgil & Sons, a retail gems and jewellery company, has received SEBI’s nod to raise ₹500 crore through an IPO. The Pune-based company filed papers with SEBI for the IPO in May.
HDB 500180 HDFCBANK

1
RIL’s market capitalisation breaches Rs 7 lakh-cr mark, India’s 2nd company to achieve the mark after TCS

2018-07-19 freepressjournal.in
New Delhi: The market valuation of Reliance Industries today surged past Rs 7 lakh crore mark in the morning trade, making it the second company after TCS to achieve this milestone.
532540 500325 HDB 500180 RELIANCE RIGD TCS HDFCBANK TTNQY RLNIY

5
Sensex hits fresh record high on firm global cues

2018-07-19 freepressjournal.in
Mumbai: The BSE Sensex hit a fresh record high of 36,740.07 points in opening session today driven by smart gains in Infosys, Coal India and Wipro, despite weak macroeconomic data released yesterday.
500820 500469 FEDA ASIANPAINT 533278 500470 532187 532461 FEDS HDFCBANK 500570 FEDERALBNK TATAMOTORS CLNDY SBAZ INDUSINDBK FDBAY TTST PNJZY TATASTEEL TATLY HDB 500180 PNB COALINDIA TTM

1
Sensex slips from record on profit-booking

2018-07-19 freepressjournal.in
Mumbai: The BSE Sensex retreated from record high to end flat at 36,541.63 today in volatile trade as investors booked profit in recent gainers despite firm global cues.
BAJAJ-AUTO 500325 RELIANCE 532977 BHRQY 533278 532215 500470 AXISBANK RIGD HDFCBANK HEROMOTOCO BHARTIARTL CLNDY RLNIY YESBANK AXB IBN 532648 YYBKY AXBKY 500182 532454 AXBA ICICIBANK TTST TATASTEEL TATLY HDB 532174 500180 HRTQY COALINDIA

5
Sensex falls 218 pts, Nifty below 11k as WPI inflation races to 4-yr high

2018-07-19 freepressjournal.in
Mumbai: The benchmark BSE Sensex dropped by around 218 points or 0.60 per cent due to sell-off in banking, pharma, and metal stocks as investors turned cautious after wholesale inflation surged to a four-year high. The broad-based Nifty cracked below the 11,000-mark as 35 of its constituents closed in the red, led by Dr Reddy’s, Tata Steel and Lupin.
IBN HINDUNILVR BHRQY 533278 VEDL 532454 ICICIBANK 500470 TTST TATASTEEL TATLY HDB 532174 500180 500696 HDFCBANK 500570 BHARTIARTL TATAMOTORS CLNDY COALINDIA TTM

1
Opinion I What HUL and Bajaj Corp results say about the rural economy

2018-07-19 moneycontrol
It’s early days yet, but the June quarter earnings of consumer good companies indicate that the pick-up in rural demand seen in the March quarter is sustaining. But there is an element of caution with the management of some of these firms reluctant to call it a full blown recovery primarily because there are doubts about what’s driving rural demand. These good numbers also don’t square up with tales of rural distress.
BAJFINANCE HDB 500180 500696 HDFCBANK HINDUNILVR BJJQY 500034

1
HDB / HDFC Bank Ltd. FORM 6-K (Current Report of Foreign Issuer)

2018-07-18 sec.gov
Form 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
HDB

1
Podcast | Sensex ends almost 150 pts lower, Nifty below 11K; midcaps take a hit

2018-07-18 moneycontrol
Intensified selling in the last hour ensured that the market ended the day on a lower note, with the Nifty giving up 11,000-mark. The Sensex managed to close almost 150 points lower, a huge drop from the record high it achieved on Wednesday morning.
500820 JIPKY HTMEDIA JPASSOCIAT ICLQY 532822 ASIANPAINT 532532 532662 500470 TTST TATASTEEL TATLY HDB 500180 IDEA HDFCBANK

1
HDFC Bank Limited - Analysts/Institutional Investor Meet/Con. Call Updates

2018-07-18 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
HDB 500180 HDFCBANK

1
An evening walk down Dalal Street | Sensex ends almost 150 pts lower, Nifty below 11K

2018-07-18 moneycontrol
Intensified selling in the last hour ensured that the market ended the day on a lower note, with the Nifty giving up 11,000-mark. The Sensex managed to close almost 150 points lower, a huge drop from the record high it achieved on Wednesday morning.
NIITTECH 500820 JIPKY HTMEDIA JPASSOCIAT ICLQY 532822 532712 ASIANPAINT 532532 532662 532541 500470 TTST RCOM TATASTEEL TATLY HDB 500180 IDEA HDFCBANK

1
HDFC shares hit record high ahead of Rs 2,800cr AMC IPO next week

2018-07-18 moneycontrol
Housing Development Finance Corporation share price gained 1.2 percent intraday on Wednesday after its subsidiary HDFC Asset Management Company decided to open the initial public offering for subscription next week.
523405 SLFPF SL IIFL HDFC 532636 HDB 500180 HDFCBANK 500010 HDFC JMFINANCIL SLFPY

1
HDFC Bank stock gains 2% to hit all-time high after raising funds from parent firm

2018-07-18 moneycontrol
HDFC Bank share price rallied 2 percent intraday to hit a fresh record high of Rs 2,219 on Wednesday after raising of funds from its parent firm.
HDB 500180 HDFCBANK HDFC 500010 HDFC

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

CUSIP: 40415F101